Forte Biosciences is a speculative, cash-burning biotech with sub-floor quality and heavily bearish options positioning, where an overbought bear-market rally masks an unresolved binary risk profile.
Thesis pillars
- Cash Burning Quality Below Floor→Stable
- Elevated Put Call Bearish Options Positioning→Stable
- Speculative Binary Biotech No Edge→Stable
- +2 more pillars — see the Why tab for full reasoning
Forte Biosciences, Inc. (FBRX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $21.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Forte Biosciences is a clinical-stage biopharmaceutical company whose lead and essentially only product candidate is FB102, an anti-CD122 monoclonal antibody targeting autoimmune diseases. FB102 has completed Phase 1 healthy-volunteer trials and shown positive Phase 1b data in... Read more
Sell if holding. Engine safety override at $21.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.1/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Forte Biosciences, Inc.
About Forte Biosciences, Inc.
Forte Biosciences' entire clinical pipeline rests on FB102, an anti-CD122 monoclonal antibody that showed a statistically significant benefit on the primary histological endpoint in a Phase 1b celiac disease study reported in June 2025, prompting a Phase 2 celiac trial that began in July 2025 with an FDA-cleared U.S. arm as of November 2025. The company held approximately $77.0 million in cash as of December 31, 2025 and has no approved products or product revenue, funding operations entirely through private placements and public equity offerings.
FB102 blocks CD122, a shared subunit of the IL-2 and IL-15 receptors that regulates NK cells and certain T-cell subsets; in Phase 1b celiac disease testing, patients receiving FB102 showed a statistically significant improvement on the VCIEL histological composite endpoint versus placebo (p=0.0099) alongside reduced intraepithelial lymphocyte density and fewer gluten-challenge GI symptoms. Beyond celiac disease, Forte is running a Phase 1b trial in non-segmental vitiligo (topline data expected first half of 2026) and has initiated a Phase 1b study in alopecia areata (data expected 2026), and management points to type 1 diabetes as a further potential indication given CD8+ T-cell and IL-15 involvement in beta-cell destruction. Forte outsources all manufacturing to third-party contract manufacturing organizations and all preclinical and clinical operations to contract research organizations, raising $75.0 million in fiscal 2025 through private placements and public offerings to fund this externalized development model.
Show full overview
Forte's own risk disclosure states plainly that its business is almost entirely dependent on the success of developing FB102, with no second clinical asset to fall back on if any of the ongoing trials disappoint. That single-asset exposure is compounded by a manufacturing dependency the 10-K also flags: Forte sources critical raw materials and services from one or a limited number of suppliers with potentially long lead times or limited manufacturing and testing slot availability, so a supply interruption at any one vendor could delay the Phase 2 celiac readout, the vitiligo and alopecia areata data expected in 2026, or all three simultaneously.
See also: Healthcare · Biotechnology
From Forte Biosciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineFB10210-K Item 1A: 'Forte's business is almost entirely dependent on the success of developing FB102, which may not be successful.'
- MEDIUMSuppliercritical raw material and manufacturing suppliers10-K Item 1: 'we source critical raw materials and services from one or a limited number of suppliers with potentially long lead times or limited manufacturing and testing slot availability'
Material Events(8-K, last 90d)
- 2026-06-02Item 5.02LOWAt the 2026 annual meeting, stockholders approved a further amendment and restatement of the 2021 Equity Incentive Plan, adding 1,850,000 newly requested shares to the pool. Routine equity-plan governance action; no officer or director departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $19.41. Score 4.1/10, moderate confidence.
Take-profit target: $21.94 (+5.1% upside). Prior stop was $19.41. Stop-loss: $19.41.
Concentration risk — Pipeline: FB102; DATA_ISSUE: analyst_target_implausible (raw $63.75 vs price $20.87 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).
Forte Biosciences, Inc. trades at a P/E of N/A (forward -5.1). TrendMatrix value score: 5.0/10. Verdict: Sell.
11 analysts cover FBRX with a consensus score of 4.2/5. Average price target: $64.
What does Forte Biosciences, Inc. do?Forte Biosciences is a clinical-stage biopharmaceutical company whose lead and essentially only product candidate is...
Forte Biosciences is a clinical-stage biopharmaceutical company whose lead and essentially only product candidate is FB102, an anti-CD122 monoclonal antibody targeting autoimmune diseases. FB102 has completed Phase 1 healthy-volunteer trials and shown positive Phase 1b data in celiac disease (reported June 2025), with an ongoing Phase 2 celiac trial (U.S. arm IND cleared November 2025) and Phase 1b trials underway in non-segmental vitiligo and alopecia areata, both expected to read out in 2026. The company had approximately $77.0 million in cash as of December 31, 2025 and outsources all manuf